Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a registered direct offering and a concurrent private ...

Scientists discovered years ago that the hypothalamus—which helps to manage body temperature, hunger, sex drive, sleep and ...

In other recent news, Palatin Technologies has completed the enrollment phase of its Phase 2 clinical trial for PL8177, a melanocortin-1 receptor agonist being tested for ulcerative colitis. The ...

"The central melanocortin system has a fundamental role in regulating energy storage and feeding behaviors. MC4R is a well validated target for treating obesity with MC4R agonists having ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

She first joined the Centre for Endocrinology in 2005 to undertake her PhD investigating a novel receptor trafficking protein MRAP2 (melanocortin receptor accessory protein two). This was funded by a ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...